BR112018071031A2 - combinações para o tratamento de neoplasmas utilizando o direcionamento de células-alvo inativas e inibidores de egfr - Google Patents
combinações para o tratamento de neoplasmas utilizando o direcionamento de células-alvo inativas e inibidores de egfrInfo
- Publication number
- BR112018071031A2 BR112018071031A2 BR112018071031-8A BR112018071031A BR112018071031A2 BR 112018071031 A2 BR112018071031 A2 BR 112018071031A2 BR 112018071031 A BR112018071031 A BR 112018071031A BR 112018071031 A2 BR112018071031 A2 BR 112018071031A2
- Authority
- BR
- Brazil
- Prior art keywords
- targeting
- combinations
- target cells
- treating neoplasms
- egfr inhibitors
- Prior art date
Links
- 206010028980 Neoplasm Diseases 0.000 title abstract 3
- 229940121647 egfr inhibitor Drugs 0.000 title 1
- 230000008685 targeting Effects 0.000 title 1
- 108060006698 EGF receptor Proteins 0.000 abstract 1
- 238000011394 anticancer treatment Methods 0.000 abstract 1
- 201000011510 cancer Diseases 0.000 abstract 1
- 239000003795 chemical substances by application Substances 0.000 abstract 1
- 239000003814 drug Substances 0.000 abstract 1
- 230000002401 inhibitory effect Effects 0.000 abstract 1
- 238000000034 method Methods 0.000 abstract 1
- 239000000203 mixture Substances 0.000 abstract 1
- 230000001613 neoplastic effect Effects 0.000 abstract 1
- 229940124597 therapeutic agent Drugs 0.000 abstract 1
- 238000011282 treatment Methods 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Oncology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Hematology (AREA)
- Pulmonology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201662323537P | 2016-04-15 | 2016-04-15 | |
| US62/323,537 | 2016-04-15 | ||
| PCT/US2017/027719 WO2017181075A1 (en) | 2016-04-15 | 2017-04-14 | Combinations for the treatment of neoplasms using quiescent cell targeting and egfr inhibitors |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| BR112018071031A2 true BR112018071031A2 (pt) | 2019-02-12 |
Family
ID=60039950
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BR112018071031-8A BR112018071031A2 (pt) | 2016-04-15 | 2017-04-14 | combinações para o tratamento de neoplasmas utilizando o direcionamento de células-alvo inativas e inibidores de egfr |
Country Status (11)
| Country | Link |
|---|---|
| US (3) | US10322128B2 (enExample) |
| EP (1) | EP3442505A4 (enExample) |
| JP (2) | JP7123806B2 (enExample) |
| KR (2) | KR20230020565A (enExample) |
| CN (1) | CN109562176A (enExample) |
| AU (2) | AU2017248762A1 (enExample) |
| BR (1) | BR112018071031A2 (enExample) |
| CA (1) | CA3021021A1 (enExample) |
| IL (2) | IL262323B (enExample) |
| MX (2) | MX2018012511A (enExample) |
| WO (1) | WO2017181075A1 (enExample) |
Families Citing this family (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA3009350A1 (en) * | 2016-01-05 | 2017-07-13 | The Trustees Of Columbia University In The City Of New York | Compositions and methods for regulating activity of inhibitor of dna binding-2 (id2) protein |
| US10322128B2 (en) | 2016-04-15 | 2019-06-18 | Felicitex Therapeutics, Inc. | Combinations for the treatment of neoplasms using quiescent cell targeting with EGFR inhibitors |
| CN109313197A (zh) | 2016-04-15 | 2019-02-05 | 费利克斯疗法公司 | 使用静止细胞靶向和有丝分裂抑制剂的用于治疗肿瘤的组合 |
| CN113557237B (zh) | 2019-01-18 | 2025-01-14 | 沃若诺伊公司 | 吡咯并吡啶衍生物及其预防或治疗蛋白激酶相关疾病的用途 |
| WO2020235973A1 (ko) * | 2019-05-22 | 2020-11-26 | 주식회사 보로노이 | 암의 예방 및/또는 치료를 위한 피롤로-피리딘 유도체 화합물의 신규 용도 |
| KR20220081631A (ko) | 2020-12-09 | 2022-06-16 | 보로노이 주식회사 | 염증성 질환의 예방 및/또는 치료를 위한 피롤로-피리딘 유도체 화합물의 신규 용도 |
| JP2024523861A (ja) * | 2021-06-15 | 2024-07-02 | ジェネンテック， インコーポレイテッド | がんを処置するための併用療法におけるｅｇｆｒ阻害剤およびｐｅｒｋ活性化剤、ならびにこれらの使用 |
| AU2022426699A1 (en) | 2021-12-30 | 2024-07-11 | Biomea Fusion, Inc. | Pyrazine compounds as inhibitors of flt3 |
| CN115947673B (zh) * | 2022-12-19 | 2024-03-15 | 湖南岳靶生物医药有限公司 | 一种化疗药物增敏剂、组合物及其应用 |
| CN116212030A (zh) * | 2023-03-03 | 2023-06-06 | 河南真实生物科技有限公司 | 包含阿兹夫定的抗肿瘤药物组合物 |
Family Cites Families (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP2560004A1 (de) * | 2011-08-19 | 2013-02-20 | DST Diagnostische Systeme & Technologien GmbH | Neues PoC-Testsystem und Verfahren |
| US9446044B2 (en) * | 2011-08-19 | 2016-09-20 | Diaxonhit | DYRK1 inhibitors and uses thereof |
| RU2016117729A (ru) | 2012-10-10 | 2017-11-10 | Фелиситекс Терапеутикс, Инк. | Терапия рака путем таргетинга покоящихся раковых клеток |
| CA2854542A1 (en) * | 2013-06-18 | 2014-12-18 | 4Sc Discovery Gmbh | Method of inhibiting dyrk1b |
| MA39763A (fr) * | 2014-03-20 | 2017-01-25 | Samumed Llc | Indazole-3-carboxamides 5-substitués, et préparation et utilisation de ceux-ci |
| EP3191523B1 (en) | 2014-09-08 | 2019-08-07 | Yeda Research and Development Co., Ltd. | Compositions and methods for treating cancer resistant to a tyrosine kinase inhibitor (tki) |
| US20170304313A1 (en) * | 2014-10-06 | 2017-10-26 | Novartis Ag | Therapeutic Combination For The Treatment Of Cancer |
| CN108135871B (zh) | 2015-07-23 | 2022-11-04 | 博蔚医药生物科技股份有限公司 | 阻断疾病的泛素化-蛋白酶体系统的胺萘醌化合物及医药组合物 |
| US10322128B2 (en) * | 2016-04-15 | 2019-06-18 | Felicitex Therapeutics, Inc. | Combinations for the treatment of neoplasms using quiescent cell targeting with EGFR inhibitors |
| CN109313197A (zh) | 2016-04-15 | 2019-02-05 | 费利克斯疗法公司 | 使用静止细胞靶向和有丝分裂抑制剂的用于治疗肿瘤的组合 |
-
2017
- 2017-04-14 US US15/488,116 patent/US10322128B2/en active Active
- 2017-04-14 JP JP2018554361A patent/JP7123806B2/ja active Active
- 2017-04-14 AU AU2017248762A patent/AU2017248762A1/en not_active Abandoned
- 2017-04-14 WO PCT/US2017/027719 patent/WO2017181075A1/en not_active Ceased
- 2017-04-14 EP EP17783286.2A patent/EP3442505A4/en not_active Withdrawn
- 2017-04-14 CN CN201780037696.7A patent/CN109562176A/zh active Pending
- 2017-04-14 KR KR1020237002826A patent/KR20230020565A/ko not_active Ceased
- 2017-04-14 KR KR1020187033052A patent/KR102494174B1/ko active Active
- 2017-04-14 MX MX2018012511A patent/MX2018012511A/es unknown
- 2017-04-14 BR BR112018071031-8A patent/BR112018071031A2/pt not_active Application Discontinuation
- 2017-04-14 CA CA3021021A patent/CA3021021A1/en active Pending
-
2018
- 2018-10-11 IL IL262323A patent/IL262323B/en unknown
- 2018-10-12 MX MX2023000549A patent/MX2023000549A/es unknown
-
2019
- 2019-06-17 US US16/442,973 patent/US11202779B2/en active Active
-
2021
- 2021-12-08 IL IL288777A patent/IL288777A/en unknown
- 2021-12-20 US US17/556,869 patent/US20220110940A1/en not_active Abandoned
-
2022
- 2022-08-08 JP JP2022126194A patent/JP2022145800A/ja active Pending
-
2023
- 2023-01-27 AU AU2023200428A patent/AU2023200428A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| CA3021021A1 (en) | 2017-10-19 |
| US11202779B2 (en) | 2021-12-21 |
| US20220110940A1 (en) | 2022-04-14 |
| KR20180132882A (ko) | 2018-12-12 |
| CN109562176A (zh) | 2019-04-02 |
| MX2023000549A (es) | 2023-02-13 |
| IL262323A (en) | 2018-11-29 |
| KR20230020565A (ko) | 2023-02-10 |
| AU2017248762A1 (en) | 2018-11-01 |
| JP7123806B2 (ja) | 2022-08-23 |
| IL288777A (en) | 2022-02-01 |
| KR102494174B1 (ko) | 2023-02-02 |
| JP2019511554A (ja) | 2019-04-25 |
| IL262323B (en) | 2022-03-01 |
| US20190298723A1 (en) | 2019-10-03 |
| JP2022145800A (ja) | 2022-10-04 |
| MX2018012511A (es) | 2019-07-08 |
| US20170296541A1 (en) | 2017-10-19 |
| EP3442505A1 (en) | 2019-02-20 |
| US10322128B2 (en) | 2019-06-18 |
| EP3442505A4 (en) | 2019-12-18 |
| AU2023200428A1 (en) | 2023-03-02 |
| WO2017181075A1 (en) | 2017-10-19 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| BR112018071031A2 (pt) | combinações para o tratamento de neoplasmas utilizando o direcionamento de células-alvo inativas e inibidores de egfr | |
| EA201992251A1 (ru) | Противораковые вакцины и способы лечения с их применением | |
| BR112018073920A2 (pt) | inibidores de pd-1/pd-l1 para tratamento de câncer". | |
| PH12017500070A1 (en) | Methods of treating cancer using tigit inhibitors and anti-cancer agents | |
| MX382902B (es) | Inhibidor de la vía noth en combinación con un agente inmunoterapéutico para usarse en el tratamiento de cáncer. | |
| MX393976B (es) | Inhibidores de muerte programada 1 (pd-19) /ligando de muerte programada 1 (pd-l1) para el tratamiento de cáncer. | |
| MX2022012146A (es) | Combinaciones para el tratamiento de neoplasias utilizando localizacion de celulas quiescentes e inhibidores de la mitosis. | |
| BR112017008628A2 (pt) | terapia de combinação compreendendo agonistas de ligação a ox40 e inibidores de tigit | |
| MX359227B (es) | Tratamiento de cáncer con inhibidores de tor cinasa. | |
| MX381582B (es) | Terapia de combinacion para el tratamiento de neoplasias malignas. | |
| BR112013002012A2 (pt) | métodos e composições para terapia de câncer de fígado | |
| MX385315B (es) | Composiciones y metodos para inhibir actividad de arginasa. | |
| MX2016007351A (es) | Terapia de combinacion para tratar cancer. | |
| BR112022008295A2 (pt) | Inibição combinada de pd-1, tgfbeta e tigit para o tratamento de câncer | |
| CA2909625C (en) | Combination therapy comprising a tor kinase inhibitor and a 5-substituted quinazolinone compound for treating cancer | |
| MX2019003722A (es) | Composiciones inmunogénicas de tert y métodos de tratamiento que las utilizan. | |
| BR112019001398A2 (pt) | métodos para tratamento de câncer de próstata | |
| MX2015010791A (es) | Metodos para tratar el cancer y prevenir la resistencia a farmacos. | |
| MX348941B (es) | Medios y metodos para trata y/o prevenir el cancer dependiente del ligando natural de receptor de aril-hidrocarburo. | |
| MX385762B (es) | Métodos para el control transcripcional objetivo en regiones del super mejorador. | |
| BR112015026257A2 (pt) | terapia de combinação compreendendo um composto di-hidropirazino-pirazina e um antagonista do receptor de andrógeno para tratar câncer de próstata | |
| EA201990567A1 (ru) | Комбинированная терапия с ингибиторами глутаминазы | |
| BR112018075135A2 (pt) | combinações farmacêuticas para tratar câncer | |
| MX2019013862A (es) | Terapia de combinacion. | |
| MX390320B (es) | Farmaco de combinacion. |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| B11A | Dismissal acc. art.33 of ipl - examination not requested within 36 months of filing | ||
| B11Y | Definitive dismissal - extension of time limit for request of examination expired [chapter 11.1.1 patent gazette] | ||
| B350 | Update of information on the portal [chapter 15.35 patent gazette] |